Loading clinical trials...

Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort Study | Clinical Trials | Clareo Health

COMPLETEDNA

Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort Study

NCT03554226•University Hospital, Toulouse

Summary

General Hypothesis: hypothesize that A / A symptoms of AD follow a particular course, influenced by associated factors, and a prospective longitudinal observational study specifically evaluating A / A symptoms in patients with MA, living in an institution and at home, would provide useful data for both clinical practice and research. Specific Hypothesis: hypothesize that in patients with AD with clinically significant A / A there is a correlation between assessment of A / A severity based on specific scales of A / A and overall impression assessment of clinical improvement or worsening of these symptoms by the clinician.

Eligibility

Age

60 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1256/5000
•Patient with AD according to NINCDS-ADRDA criteria with or without cerebrovascular component at all stages of the disease.
•Patient with agitation / aggression (A / A) type SPCDs, assessed with a score ≥ 4 of at least 1 of the A / A domains, disinhibition, irritability and / or aberrant motor behavior of the NPI scale, with a score frequency ≥2 during the inclusion visit.
•Participation agreement signed by the patient or, in the event of the patient's incapacity, by his / her legal representative or, as the case may be, by the person of trust or family. The patient's ability to sign informed consent is evaluated by a clinician experienced in the field of dementia.
•Patient with social security
•If the patient lives at home:
•Presence of a clearly identified primary caregiver: Person from the entourage of the patient who assumes the main part of the care (at least 2 hours at least 3 times during the week) able to complete the questionnaires and to evaluate the patient.
•Availability and agreement of the carer to accompany the patient during consultations.
•If the patient lives in an institution:
•He / she must have been there for at least 2 months before inclusion.

Exclusion Criteria

•745/5000
•Brain pathology (other than AD) that may be the cause of dementia: extensive cerebrovascular disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, brain trauma.
•A / A secondary to concomitant medications, or to a medical or psychiatric condition
•Concurrent major depressive episode (DSM-IV).
•Psychotic symptoms of delirium type and hallucination clinically significant (score ≥ 4 field delusions and / or hallucinations of the NPI scale).
•Presence of concomitant pathologies preventing participation in the study (testing and / or study visits).
•Concurrent participation in another research that may influence the testing of our study.

Locations (1)

Toulouse University Hospital (CHU de Toulouse)

Toulouse, France

Key Dates

Start Date

November 1, 2014

Primary Completion Date

December 31, 2018

Completion Date

December 31, 2018

Last Updated

October 14, 2021

Enrollment

270

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

NeuroPsychiatric Inventory Clinician (NPI-C)

BEHAVIORAL

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 14, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Agitation and Aggressivity in Alzheimer's Disease Patients: A Cohort Study

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease